Abstract Number: 0429 • ACR Convergence 2022
No Change in Serum Levels of Bone Turnover Markers Corrected for Age and Gender During the First Year of Secukinumab Treatment in Patients with Ankylosing Spondylitis
Background/Purpose: In patients with ankylosing spondylitis (AS), TNF-α inhibitors influence the course of serum bone turnover markers (BTM), favoring an increase in mineralization during the…Abstract Number: 1045 • ACR Convergence 2022
Quantification of the Enthesic Response to Biological Therapies in Patients with Spondyloarthritis by Computer Analysis of Ultrasound Images
Background/Purpose: Enthesitis is the base of the pathophysiology of spondyloarthritis. Recently, our research group has shown that computer analysis of static images can be used…Abstract Number: 1497 • ACR Convergence 2022
How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? – Real World Data from a German Observational Study with Secukinumab
Background/Purpose: In both, ankylosing spondylitis (AS) and psoriatic arthritis (PsA), women typically have a longer delay in diagnosis.1,2 There is scientific evidence that prognosis for…Abstract Number: 0292 • ACR Convergence 2022
Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Background/Purpose: Increased risk of malignancies has been associated with chronic inflammation, as well as immunosuppressive and immunomodulatory therapies. The objective of this analysis is to…Abstract Number: 0406 • ACR Convergence 2022
Are the BASDAI & BASFI Capturing the Full Impact of Disease Activity on Quality of Life in Women with Axial Spondyloarthritis?
Background/Purpose: The tools to assess disease activity and quality of life in axial spondyloarthritis (axSpA) were developed in ankylosing spondylitis cohorts biased towards inclusion of…Abstract Number: 0430 • ACR Convergence 2022
The Course of Bone Mineral Density During 8 Years of Treatment with TNF-α Inhibitors in Patients with Ankylosing Spondylitis
Background/Purpose: Bone loss reflected by lower bone mineral density (BMD) compared to age and gender matched healthy controls is a common feature of ankylosing spondylitis…Abstract Number: 1112 • ACR Convergence 2022
Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry
Background/Purpose: In routine care, biosimilar-to-biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of switches from…Abstract Number: 1509 • ACR Convergence 2022
Patient Clusters Identified by Machine Learning from a Pooled Analysis of the Clinical Development Program of Secukinumab in Psoriatic Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis with Axial Manifestations
Background/Purpose: Universally acceptable clinical and imaging criteria to define axial psoriatic arthritis (PsA) is lacking.1 Machine learning (ML) algorithms can detect patterns from large clinical…Abstract Number: 0157 • ACR Convergence 2021
Development of a Deep Learning Algorithm for the Detection of Sacroiliitis on MRI in Patients with Active Axial Spondyloarthritis
Background/Purpose: Magnetic resonance imaging (MRI) plays a critical role in assisting the diagnosis of axial spondyloarthritis (axSpA). There are many characteristic MRI lesions that can…Abstract Number: 0384 • ACR Convergence 2021
A Tough Cell: The Argument for a Biomarker of Clinical and Imaging Outcomes in Spondyloarthritis: The Neutrophil Lymphocyte Ratio and the Platelet Lymphocyte Ratio
Background/Purpose: Biomarkers of disease activity/severity and imaging outcomes in axial spondyloarthritis (axSpA) remain a challenge. The most common relevant biomarker is the C-Reactive Protein (CRP),…Abstract Number: 0900 • ACR Convergence 2021
The Phenomenon of Fused Sacroiliac Joints but Absent Syndesmophytes in Long Standing Ankylosing Spondylitis Patients: Data from a Prospectively Followed Cohort
Background/Purpose: Ankylosing Spondylitis describes disorders of inflammation and damage to the spine and sacroiliac (SI) joints. Clinicians have observed, on occasion, AS subjects with fused…Abstract Number: 0923 • ACR Convergence 2021
Minimal Impact of the COVID-19 Pandemic on Patient-Reported Disease Activity and Health-Related Quality of Life in Patients with Ankylosing Spondylitis Receiving Bimekizumab: Post Hoc Analyses from a Phase 2b Study
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that inhibits both interleukin (IL)-17A and IL-17F, has been demonstrated to be efficacious and well tolerated in patients…Abstract Number: 1322 • ACR Convergence 2021
Body Mass Index (BMI) Underestimates Obesity in Females with Axial Spondyloarthropathy
Background/Purpose: Worldwide prevalence of obesity has been steadily increasing, despite public health campaigns to raise awareness. In axial spondyloarthropathy (axSpA) obesity has been shown to…Abstract Number: 0158 • ACR Convergence 2021
The Influence of Age on the Prevalence of Inflammatory and Post-inflammatory MRI Lesions in the Sacroiliac Joints of Patients with and Without Axial Spondyloarthritis
Background/Purpose: Axial spondyloarthritis (axSpA) is clinically characterized by chronic inflammatory back pain and by inflammatory and structural changes in the sacroiliac joint (SIJ) as assessed…Abstract Number: 0385 • ACR Convergence 2021
The Diagnostic Utility of Serum interleukin-22 in Patients with Suspected Axial Spondyloarthritis
Background/Purpose: There is an unmet need for a reliable biomarker for the diagnosis and differentiation of AxSpA from its multiple mimickers. Serum levels of IL-22,…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 62
- Next Page »